Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023. This is a video synopsis/summary of a Post Conference Perspectives involving ...
How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival. Now let’s move to the CheckMate-77T trial, which evaluated perioperative ...
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of ...
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer ...
Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful ...
It’s not a proper market showdown without all the players. And in the perioperative treatment of early-stage, non-small cell lung cancer with a PD-1/L1 inhibitor, the field is quickly taking shape.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results